Review Article

Meta-Analysis of Atrial Fibrillation Ablation in Patients with Systolic Heart Failure

Table 2

Medications use after randomization.

KhanMacDonaldJonesHunterDi BiasePrabhuMarrouche
Ablation armAV ablation/ CRTAblation armRate controlAblation armRate controlAblation armRate controlAblation armAmiodaroneAblation armrate controlAblation armMedical therapy

Rate control NANAβB ± digoxinβB ± digoxinβB ± digoxinβB ± digoxinβBβBβB ± digoxinβB ± digoxinβBβBβB ± digoxinβB ± digoxin

AAD5 patients received amiodarone, 4 received class III AAD and 1 received class IC AAD14 patients received amiodarone and 1 received class III AADOral amiodarone for 3 months in all patientsNoneAAD stopped post ablation unless indicated by other reasonsNoneAAD stopped post ablation unless indicated by other reasonsNoneAAD allowed for 3 months after the first ablationAmiodarone in all9 patients received amiodarone and 3 received sotalolNone45 patients received amiodarone, and 2 received sotalol56 patients received amiodarone, and 6 received sotalol

AnticoagulationWarfarin for at least 3 months, then at the discretion
of the treating physician
NAWarfarinWarfarinN/AN/AWarfarinWarfarinN/AN/APer guidelinesPer guidelinesWarfarin for at least 6 months, then at the discretion
of the treating physician
Per guidelines

AAD: antiarrhythmic drugs, B: beta-blockers, and NA: not available.